DK1263503T3 - Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper - Google Patents
Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypperInfo
- Publication number
- DK1263503T3 DK1263503T3 DK01918367T DK01918367T DK1263503T3 DK 1263503 T3 DK1263503 T3 DK 1263503T3 DK 01918367 T DK01918367 T DK 01918367T DK 01918367 T DK01918367 T DK 01918367T DK 1263503 T3 DK1263503 T3 DK 1263503T3
- Authority
- DK
- Denmark
- Prior art keywords
- cyanoquinolines
- treatment involves
- colon polyps
- involves inhibition
- inhibition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- General Preparation And Processing Of Foods (AREA)
- Compounds Of Unknown Constitution (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52419600A | 2000-03-13 | 2000-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1263503T3 true DK1263503T3 (da) | 2006-02-13 |
Family
ID=24088181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01918367T DK1263503T3 (da) | 2000-03-13 | 2001-03-06 | Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1263503B1 (zh) |
JP (1) | JP2003526686A (zh) |
KR (2) | KR20080009294A (zh) |
CN (1) | CN1190197C (zh) |
AR (1) | AR035482A1 (zh) |
AT (1) | ATE308364T1 (zh) |
AU (2) | AU2001245452B2 (zh) |
BR (1) | BR0109165A (zh) |
CA (1) | CA2402742C (zh) |
DE (1) | DE60114580T2 (zh) |
DK (1) | DK1263503T3 (zh) |
EA (1) | EA200200976A1 (zh) |
ES (1) | ES2248302T3 (zh) |
HK (1) | HK1048775B (zh) |
HU (1) | HUP0300547A2 (zh) |
IL (2) | IL151249A0 (zh) |
MX (1) | MXPA02008836A (zh) |
NO (1) | NO20024356L (zh) |
NZ (1) | NZ521117A (zh) |
PL (1) | PL202873B1 (zh) |
TW (1) | TWI262805B (zh) |
WO (1) | WO2001068186A2 (zh) |
ZA (1) | ZA200208178B (zh) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576644B2 (en) | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
EP1477481B1 (en) * | 2002-01-28 | 2009-07-22 | Ube Industries, Ltd. | Process for producing quinazolin-4-one derivative |
BR0307375A (pt) * | 2002-02-05 | 2004-12-07 | Wyeth Corp | Processo para a sìntese de ácidos n-acil-2-amino-4-alcóxi-5-nitro-benzóicos |
EP1499593A4 (en) * | 2002-04-30 | 2006-02-01 | Yungjin Pharmacautical Co Ltd | CHINOLINE DERIVATIVES AS CASPASE-3 INHIBITOR, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
EP2277867B1 (en) | 2002-07-15 | 2012-12-05 | Symphony Evolution, Inc. | Compounds, pharmaceutical compositions thereof and their use in treating cancer |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
CA2529611C (en) | 2002-12-20 | 2009-12-15 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
ES2371383T3 (es) | 2003-09-26 | 2011-12-30 | Exelixis, Inc. | N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer. |
TW200529846A (en) | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
WO2005111016A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
BRPI0511132A (pt) | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina e composição farmacêutica compreendendo os mesmos |
BRPI0510980A (pt) | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento do crescimento anormal de células |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
EP1833482A4 (en) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
JP2008542266A (ja) * | 2005-05-25 | 2008-11-27 | ワイス | 6−アルキルアミノキノリン誘導体の合成方法 |
EP3173084B1 (en) | 2005-11-11 | 2019-10-23 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
DE102006029446A1 (de) * | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Neue 3-substituierte-Chinoline als Kinase-Inhibitoren |
DE102006029445A1 (de) * | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Neue 3-Cyano-chinoline als Kinase-Inhibitoren |
RU2492864C2 (ru) | 2006-09-18 | 2013-09-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения рака, несущего мутации egfr |
DE102007024470A1 (de) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren |
EP2072502A1 (de) | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
TW202241853A (zh) | 2009-01-16 | 2022-11-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
JP2012531438A (ja) * | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびその使用 |
US9545381B2 (en) | 2009-07-06 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
JP6533997B2 (ja) * | 2014-12-26 | 2019-06-26 | 株式会社ヤクルト本社 | Znf143阻害活性を有する化合物およびその利用 |
CN107849022A (zh) * | 2015-04-10 | 2018-03-27 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物和其使用方法 |
EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
AU2016355433C1 (en) | 2015-11-16 | 2021-12-16 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
US10736897B2 (en) | 2017-05-25 | 2020-08-11 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
BR112019024674A2 (pt) | 2017-05-25 | 2020-06-16 | Araxes Pharma Llc | Inibidores covalentes da kras |
WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
ATE341341T1 (de) * | 1999-08-12 | 2006-10-15 | Wyeth Corp | Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs |
-
2001
- 2001-03-06 BR BR0109165-4A patent/BR0109165A/pt not_active Application Discontinuation
- 2001-03-06 WO PCT/US2001/007068 patent/WO2001068186A2/en active IP Right Grant
- 2001-03-06 EA EA200200976A patent/EA200200976A1/ru unknown
- 2001-03-06 JP JP2001566747A patent/JP2003526686A/ja not_active Withdrawn
- 2001-03-06 DK DK01918367T patent/DK1263503T3/da active
- 2001-03-06 HU HU0300547A patent/HUP0300547A2/hu unknown
- 2001-03-06 CA CA002402742A patent/CA2402742C/en not_active Expired - Fee Related
- 2001-03-06 PL PL363072A patent/PL202873B1/pl not_active IP Right Cessation
- 2001-03-06 AT AT01918367T patent/ATE308364T1/de not_active IP Right Cessation
- 2001-03-06 ES ES01918367T patent/ES2248302T3/es not_active Expired - Lifetime
- 2001-03-06 KR KR1020077027115A patent/KR20080009294A/ko not_active Application Discontinuation
- 2001-03-06 AU AU2001245452A patent/AU2001245452B2/en not_active Ceased
- 2001-03-06 IL IL15124901A patent/IL151249A0/xx active IP Right Grant
- 2001-03-06 CN CNB018093981A patent/CN1190197C/zh not_active Expired - Fee Related
- 2001-03-06 KR KR1020027012074A patent/KR100817423B1/ko not_active IP Right Cessation
- 2001-03-06 MX MXPA02008836A patent/MXPA02008836A/es active IP Right Grant
- 2001-03-06 DE DE60114580T patent/DE60114580T2/de not_active Expired - Lifetime
- 2001-03-06 AU AU4545201A patent/AU4545201A/xx active Pending
- 2001-03-06 NZ NZ521117A patent/NZ521117A/en unknown
- 2001-03-06 EP EP01918367A patent/EP1263503B1/en not_active Expired - Lifetime
- 2001-03-12 TW TW090105702A patent/TWI262805B/zh active
- 2001-03-12 AR ARP010101143A patent/AR035482A1/es not_active Application Discontinuation
-
2002
- 2002-08-14 IL IL151249A patent/IL151249A/en not_active IP Right Cessation
- 2002-09-12 NO NO20024356A patent/NO20024356L/no unknown
- 2002-10-10 ZA ZA200208178A patent/ZA200208178B/en unknown
-
2003
- 2003-02-13 HK HK03101049.6A patent/HK1048775B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1263503T3 (da) | Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper | |
DK1259512T3 (da) | Pteridinforbindelser til behandling af psoreasis | |
DK1343773T3 (da) | Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser | |
DK1144395T3 (da) | 2-amino-benzoxazinon-derivater til behandling af fedme | |
NO20030230L (no) | Behandling av jernsulfidavsetninger | |
DK1294644T3 (da) | Vandbehandlingssammensætninger | |
DK1063990T3 (da) | Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser | |
DK1562932T3 (da) | 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter | |
DK1143977T3 (da) | 2-oxy-benzoxazinonderivater til behandling af obesitas | |
DK1324970T3 (da) | Retinoider til behandling af emfysem | |
DK1282616T3 (da) | Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter | |
DK1392318T3 (da) | 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse | |
DK1176964T3 (da) | Brug af ET743 til behandling af cancer | |
DK1206436T3 (da) | Retinoider til behandling af emfysem | |
DK1344526T3 (da) | Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser | |
DK1197485T3 (da) | Cyclobutendionderivater til behandling af artherosclerose | |
NO20026219L (no) | Forbindelser for behandling av svekket fundisk relaksasjon | |
DK1350521T3 (da) | Immunoterapeutiske kombinationer til behandling af tumorer | |
DK1200114T3 (da) | PPAR delta inhibitorer til behandling af kardiovaskulære sygdomme | |
DK1268482T3 (da) | Pyranoindoler til behandling af glaukom | |
DK1468996T3 (da) | Indolderivater til behandling af CNS-sygdomme | |
DK1200447T3 (da) | Oxazinocarbazoler til behandling af CNS-sygdomme | |
FR2805983B3 (fr) | Douche | |
DK1468686T3 (da) | S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser | |
DK1567524T3 (da) | Thia-epothilonderivater til behandling af cancer |